Eduard Ayuso

Eduard Ayuso is the Chief Technology Officer (CTO) at DINAMIQS, a Contract Development and Manufacturing Organization (CDMO) specializing in viral vector manufacturing for gene therapies.12 He is a highly experienced professional with over 20 years of expertise in the field of gene therapy using viral vector platforms.3

Career Highlights

Prior to his current role as CTO, Eduard Ayuso served as the CEO of DINAMIQS since its inception.1 He transitioned to the CTO position on March 1, 2024, when Martin Kessler took over as the new CEO.1 Before joining DINAMIQS, Ayuso held the position of Chief Technology Officer at DiNAQOR AG, a biotechnology company focused on gene therapies.5

Expertise and Contributions

Eduard Ayuso is recognized as an expert in gene therapy and viral vector manufacturing.3 His extensive knowledge and experience have been instrumental in building DINAMIQS into a leading CDMO in the Cell & Gene Therapy space.1 Under his leadership, DINAMIQS has developed a highly skilled team and end-to-end solutions for manufacturing viral vectors.4

Scientific Background

Ayuso has made significant contributions to the scientific community, with more than 50 published scientific papers in the field of gene therapy.3 His expertise spans various aspects of viral vector design, manufacturing, and application in gene therapies.

Role at DINAMIQS

As the CTO of DINAMIQS, Eduard Ayuso plays a crucial role in driving the company's technological advancements and innovation in viral vector manufacturing.1 He works closely with the CEO and other team members to develop and implement cutting-edge solutions for gene therapy companies.12

Eduard Ayuso's LinkedIn profile can be found under the username eduard-ayuso-b9029419b, where more details about his professional experience and accomplishments may be available.